Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be ...

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement ...

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck KGaA has agreed to buy ...

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

Merck KGaA acquires SpringWorks Therapeutics for $3.9B to enhance its cancer drug portfolio, boosting revenue growth and ...

Germany’s Merck KGaA has agreed to buy SpringWorks Therapeutics, adding the US biotech’s portfolio of cancer and rare disease ...

Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. | Merck KGaA’s protracted pursuit of ...

Fintel reports that on April 30, 2025, HC Wainwright & Co. downgraded their outlook for SpringWorks Therapeutics ...